Hui-Chu Lang (Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan) Jaw-Ching Wu (School of Medicine, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan) Sang-Hue Yen (Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan) Chung-Fu Lan (School of Medicine, Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan) Shi-Liang Wu (Population and Health Research Center, Bureau of Health Promotion, Department of Health, Taichung, Taiwan)
Abstract
Background: Hepatocellular carcinoma (HCC) is the second most common cancer in Taiwan. For males in Taiwan, it is the most dangerous cancer, with both the highest incidence and mortality rate. Objective: To determine cancer-related medical care costs for long-term survivors of HCC. Methods: The estimation of the lifetime cost was based on the insurer perspective and adopted an incidence-based approach. Data was sourced from the 1999-2002 cancer registry statistics of patients with HCC and the claims data of Taipei Veterans General Hospital (TVGH). In total there were 2873 HCC patients at TVGH. In addition to this data, the research used population National Health Insurance claims data from the National Health Research Institutes (1996-2002) as the comparison group. The probabilities of survival, dying of cancer or dying of other causes were estimated using cancer registry statistics. To estimate lifetime (10-year) cost, we divided the disease process into three phases: initial, continuing and terminal. The cost of HCC was calculated as the sum of the average cost of each phase. The expected lifetime cost for treatment of an HCC patient was estimated by incorporating the phase-specific costs with the survival and mortality rates. Results: The results showed that 895 patients survived <1 year, and treatment for each of these patients cost on average New Taiwan dollars ($NT) 206_573 ($US1_= $NT33, year 2002 value) over this period. For those who survived >=1 year, the terminal phase of treatment resulted in the highest costs, $NT237_032. On average, for each patient, the initial phase cost was $NT140_403 and the monthly cost for the continuing phase was $NT8687. For the average HCC patient, the 10-year lifetime cost was $NT418_554 (in nominal $NT). Conclusion: Our study showed that the terminal phase cost the most out of the three treatment phases. The aggregate lifetime cost of HCC is useful for health policy making and clinical decision making. DOI: 10.2165/0148365-200806010-00005
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
page. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Find related papers by JEL classification: C - Mathematical and Quantitative Methods D - Microeconomics I - Health, Education, and Welfare Z - Other Special Topics I1 - Health, Education, and Welfare - - Health I19 - Health, Education, and Welfare - - Health - - - Other I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets